Sanuwave Receives FDA De Novo Decision to Immediately Market the Dermapace System for the Treatment of Diabetic Foot Ulcers in the U.S.
January 02, 2018 08:00 ET
|
SANUWAVE Health, Inc.
SUWANEE, GA, Jan. 02, 2018 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (OTCQB: SNWV) has announced that the U.S. Food and Drug Administration (FDA) has issued its decision on the de novo submission...